Dr. Ai on Potential With Mogamulizumab in CTCL
3 Pogledi
• 08/09/23
0
0
Ugraditi
administrator
Pretplatnici
Weiyun Z. Ai, MD, PhD, assistant clinical professor, Department of Medicine, University of California San Francisco, speaks to the relevance of mogamulizumab (Poteligeo) in treating Sezary syndrome, a rare and aggressive form of cutaneous T-cell lymphoma
Prikaži više
Komentari na Facebooku
SORT BY-
Najbolji komentari
-
Najnoviji komentari